amantadine has been researched along with Depression in 44 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 7.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "Amantadine was not superior to placebo." | 6.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| "Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis." | 6.69 | Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. ( Beelitz, G; Berghöfer, A; Bode, L; Brodhun, B; Ferszt, R; Kühl, KP; Ludwig, H; Müller-Oerlinghausen, B; Severus, EW; Winzer, B, 1999) |
| "Among them, depression is a common psychiatric symptom, and links to poorer recovery." | 5.42 | Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 5.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| " Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium." | 4.79 | Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997) |
| " The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression." | 3.66 | [Psychopharmacologic spectrum of melanostatin]. ( Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV, 1980) |
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 3.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "Amantadine was not superior to placebo." | 2.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| "Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis." | 2.69 | Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. ( Beelitz, G; Berghöfer, A; Bode, L; Brodhun, B; Ferszt, R; Kühl, KP; Ludwig, H; Müller-Oerlinghausen, B; Severus, EW; Winzer, B, 1999) |
| "Amantadine treatment was used as an antidepressant and antiviral compound." | 2.69 | Word recognition memory before and after successful treatment of depression. ( Dietrich, DE; Emrich, HM; Hauser, U; Huber, TJ; Johannes, S; Kipp, K; Kleinschmidt, A; Schneider, U; Spannhuth, CW; Wieringa, BM, 2000) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "After the onset of Parkinson's disease, depression is very common." | 2.37 | Parkinson's disease in the elderly: psychiatric manifestations. ( Fonda, D, 1985) |
| "Among them, depression is a common psychiatric symptom, and links to poorer recovery." | 1.42 | Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015) |
| "In patients who had impulse control disorders at baseline (n = 119), high dopamine agonist dose was associated with the presence of disorders at follow-up." | 1.38 | Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. ( Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T, 2012) |
| "At a 1985 conference on influenza control organised by the US Centers for Disease Control, a major viewpoint expressed was for the routine immunisation of children who are household contacts of high-risk persons." | 1.27 | A perspective on influenza control. ( Imperato, PJ, 1986) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 1.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (61.36) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 5 (11.36) | 29.6817 |
| 2010's | 6 (13.64) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Maratha, S | 1 |
| Sharma, V | 1 |
| Walia, V | 1 |
| Tan, L | 1 |
| Ge, H | 1 |
| Tang, J | 1 |
| Fu, C | 1 |
| Duanmu, W | 1 |
| Chen, Y | 1 |
| Hu, R | 1 |
| Sui, J | 1 |
| Liu, X | 1 |
| Feng, H | 1 |
| Minozzi, S | 2 |
| Amato, L | 2 |
| Pani, PP | 2 |
| Solimini, R | 2 |
| Vecchi, S | 2 |
| De Crescenzo, F | 1 |
| Zuccaro, P | 2 |
| Davoli, M | 2 |
| Yu, M | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Zhang, T | 1 |
| Joutsa, J | 1 |
| Martikainen, K | 1 |
| Vahlberg, T | 1 |
| Kaasinen, V | 1 |
| Induruwa, I | 1 |
| Constantinescu, CS | 1 |
| Gran, B | 1 |
| Iwasaki, Y | 1 |
| Iguchi, H | 1 |
| Ichikawa, Y | 1 |
| Igarashi, O | 1 |
| Kawabe, S | 1 |
| Kiyozuka, T | 1 |
| Maruyama, M | 1 |
| Ikeda, K | 1 |
| Fujioka, T | 1 |
| Garssen, MP | 1 |
| Schmitz, PI | 1 |
| Merkies, IS | 1 |
| Jacobs, BC | 1 |
| van der Meché, FG | 1 |
| van Doorn, PA | 1 |
| Bonelli, RM | 1 |
| Hofmann, P | 1 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Klusha, VE | 1 |
| Svirskis, ShV | 1 |
| Jörg, J | 1 |
| Danielczyk, W | 2 |
| Moryl, E | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Young, BK | 1 |
| Camicioli, R | 1 |
| Ganzini, L | 1 |
| Huber, TJ | 2 |
| Dietrich, DE | 2 |
| Emrich, HM | 2 |
| Ferszt, R | 1 |
| Kühl, KP | 1 |
| Bode, L | 1 |
| Severus, EW | 1 |
| Winzer, B | 1 |
| Berghöfer, A | 1 |
| Beelitz, G | 1 |
| Brodhun, B | 1 |
| Müller-Oerlinghausen, B | 1 |
| Ludwig, H | 1 |
| Kleinschmidt, A | 1 |
| Hauser, U | 1 |
| Schneider, U | 1 |
| Spannhuth, CW | 1 |
| Kipp, K | 1 |
| Wieringa, BM | 1 |
| Johannes, S | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| McFarland, HR | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Casacchia, M | 1 |
| Müller, HF | 1 |
| Dastoor, DP | 1 |
| Klingner, A | 1 |
| Cole, M | 1 |
| Boillat, J | 1 |
| Mindham, RH | 1 |
| Marsden, CD | 1 |
| Parkes, JD | 1 |
| Couto, B | 1 |
| Oliveira, C | 1 |
| Mattos, JP | 1 |
| Freitas, MR | 1 |
| Lipper, S | 1 |
| Bermanzohn, PC | 1 |
| Ziedonis, DM | 1 |
| Kosten, TR | 1 |
| Imperato, PJ | 1 |
| Fonda, D | 1 |
| Vale, S | 1 |
| Espejel, MA | 1 |
| Dominguez, JC | 1 |
| Swash, M | 1 |
| Roberts, AH | 1 |
| Zakko, H | 1 |
| Heathfield, KW | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Ambrozi, L | 1 |
| Birkmayer, W | 1 |
| Neumayer, E | 1 |
| Riederer, P | 1 |
| Ananth, J | 1 |
| Ruskin, R | 1 |
| Schwab, RS | 1 |
| Poskanzer, DC | 1 |
| England, AC | 1 |
| Young, RR | 1 |
| Reveno, WS | 2 |
| Bauer, RB | 2 |
| Rosenbaum, H | 2 |
| Gehlen, W | 1 |
| Kudashov, NI | 1 |
| Vernier, VG | 1 |
| Harmon, JB | 1 |
| Stump, JM | 1 |
| Lynes, TE | 1 |
| Marvel, JP | 1 |
| Smith, DH | 1 |
| Rizzo, M | 1 |
| Morselli, PL | 1 |
| Barbieri, NF | 1 |
| Megna, GF | 1 |
| Micalizzi, V | 1 |
| Pigneri, MT | 1 |
| Puca, FM | 1 |
| Schwieger, AC | 1 |
| Jenkins, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial[NCT03336541] | Phase 4 | 64 participants (Actual) | Interventional | 2017-11-23 | Completed | ||
| A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders[NCT00344682] | Phase 4 | 31 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -4.13 |
| Memantine | -5.53 |
The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -3.69 |
| Memantine | -6.47 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures. (NCT00344682)
Timeframe: baseline and week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -10.75 |
| Memantine | -7.13 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure. (NCT00344682)
Timeframe: Baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -7.25 |
| Memantine | -7.13 |
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
12 reviews available for amantadine and Depression
| Article | Year |
|---|---|
Dopamine agonists for the treatment of cocaine dependence.
Topics: Amantadine; Antidepressive Agents; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Ag | 2015 |
Dopamine agonists for the treatment of cocaine dependence.
Topics: Amantadine; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Agonists; Humans; Levodop | 2011 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic | 1997 |
Possible use of amantadine in depression.
Topics: Amantadine; Animals; Antidepressive Agents; Depression; Depressive Disorder; Dopamine Agents; Humans | 1999 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
Parkinson's disease in the elderly: psychiatric manifestations.
Topics: Aged; Amantadine; Depression; Humans; Levodopa; Mood Disorders; Parasympatholytics; Parkinson Diseas | 1985 |
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che | 1971 |
[Biochemical aspects of human behavior].
Topics: Amantadine; Behavior; Biogenic Amines; Brain; Depression; Dihydroxyphenylalanine; Dopamine; Epinephr | 1973 |
Use of drugs in the treatment of parkinsonism.
Topics: Amantadine; Depression; Dihydroxyphenylalanine; Feeding and Eating Disorders; Humans; Hypertension; | 1970 |
[Use of amantadine in the prevention and treatment of influenza (review of the literature)].
Topics: Adolescent; Adult; Amantadine; Animals; Chick Embryo; Child; Cycloparaffins; Depression; Female; Hem | 1971 |
9 trials available for amantadine and Depression
| Article | Year |
|---|---|
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Anxiety; Cross-Over Studies; Depressio | 2006 |
Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection.
Topics: Amantadine; Analysis of Variance; Antidepressive Agents; Antiviral Agents; Borna Disease; Chronic Di | 1999 |
Word recognition memory before and after successful treatment of depression.
Topics: Adult; Aged; Amantadine; Antidepressive Agents; Antiviral Agents; Borna Disease; Cross-Over Studies; | 2000 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio | 1978 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; | 1976 |
The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Drug Therapy, Com | 1976 |
Depression as a prognostic factor for pharmacological treatment of cocaine dependence.
Topics: Adult; Amantadine; Cocaine; Depression; Desipramine; Female; Humans; Male; Prognosis; Psychiatric St | 1991 |
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.
Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me | 1987 |
Amantadine in depression.
Topics: Amantadine; Central Nervous System; Depression; Evaluation Studies as Topic; Female; Humans; Male | 1971 |
23 other studies available for amantadine and Depression
| Article | Year |
|---|---|
Possible involvement of NO-cGMP signaling in the antidepressant like Effect of Amantadine in mice.
Topics: Amantadine; Animals; Antidepressive Agents; Cyclic GMP; Depression; Glutamic Acid; Hindlimb Suspensi | 2022 |
Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats.
Topics: Amantadine; Animals; Antidepressive Agents; Apoptosis; Brain Injuries; Corpus Striatum; Depression; | 2015 |
Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress.
Topics: Amantadine; Animals; Antidepressive Agents; Blotting, Western; CA1 Region, Hippocampal; Cognition; C | 2016 |
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease | 2012 |
Fatigue and depression are associated with poor quality of life in ALS.
Topics: Adaptation, Psychological; Amantadine; Amyotrophic Lateral Sclerosis; Caregivers; Cross-Sectional St | 2003 |
[Psychopharmacologic spectrum of melanostatin].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats | 1980 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson | 1980 |
Potential antidepressive properties of amantadine, memantine and bifemelane.
Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera | 1993 |
Potential antidepressive properties of amantadine, memantine and bifemelane.
Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera | 1993 |
Potential antidepressive properties of amantadine, memantine and bifemelane.
Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera | 1993 |
Potential antidepressive properties of amantadine, memantine and bifemelane.
Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera | 1993 |
Treating parkinsonism in the era of levodopa.
Topics: Amantadine; Antidepressive Agents; Anxiety; Depression; Histamine H1 Antagonists; Humans; Levodopa; | 1975 |
Amantadine in senile dementia: electroencephalographic and clinical effects.
Topics: Administration, Oral; Aged; Amantadine; Anxiety; Dementia; Depression; Electroencephalography; Femal | 1979 |
Letter: Electroconvulsive therapy in patients with parkinsonism.
Topics: Amantadine; Atropine; Depression; Diphenhydramine; Electroconvulsive Therapy; Female; Humans; Levodo | 1975 |
A perspective on influenza control.
Topics: Adult; Aged; Amantadine; Child; Depression; Female; Health Occupations; Humans; Influenza A virus; I | 1986 |
Treatment of involuntary movement disorders with tetrabenazine.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Depression; Dystonia Musculorum Deformans; Evaluation St | 1972 |
Treatment of intractable depression.
Topics: Amantadine; Antidepressive Agents; Depression; Dextroamphetamine; Drug Therapy, Combination; Hormone | 1974 |
Amantadine in Parkinson's disease. Review of more than two years' experience.
Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism | 1972 |
L-dopa for parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum | 1973 |
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
Topics: Amantadine; Anesthetics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents; Anti | 1974 |
The toxicologic and pharmacologic properties of amantadine hydrochloride.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Amantadine; Analgesia; Animals; Arrhythmias, Cardiac; Bl | 1969 |
Amantadine-induced aggressiveness.
Topics: Aged; Aggression; Amantadine; Depression; Humans; Motor Activity | 1972 |
L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
Topics: Aged; Amantadine; Chlorides; Depression; Dihydroxyphenylalanine; Drug Hypersensitivity; Female; Foll | 1971 |
[Preliminary psychological findings during treatment of the parkinsonian syndrome with amantadine. Preliminary observations].
Topics: Amantadine; Anxiety; Depression; Dihydroxyphenylalanine; Emotions; Humans; Intelligence Tests; Menta | 1971 |
Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Muscle Tonu | 1970 |